Anti-Tumor Effect of Formononetin Triazole Derivatives on HGC-27 Cells
CUI Huanjie1, TANG Ze2, ZHAO Yan1, HAN Jiahong1, CAI Enbo1 *
In this study, a new triazole derivative of formononetin was developed based on the principle of drug molecular fragments and combination. Five kinds of cancer cells were screened by MTT method, and the compounds with the strongest anti-tumor activity and their corresponding cell lines were selected for further anti-tumor activity study. By detecting the effects of the compounds on tumor cell proliferation, migration, cycle, apoptosis and autophagy, the anti-tumor activity of the compounds was comprehensively evaluated, and the related pathways were predicted by molecular docking experiments, and the related proteins were detected. The results showed that the activity of 7-[7-(2H-1,2,3-triazole-2-yl) heptyl] formononetin ether (FN.12) on human gastric cancer cell line HGC-27 was prominent, and the IC50 value was 8.52 μmol/L. Besides, FN.12 can inhibit the proliferation and migration of HGC-27 cells, block HGC-27 cells in S phase, induce apoptosis and autophagy of HGC-27 cells, and these effects may be achieved through PI3K/Akt/mTOR signal pathway
CN
EN